

## Lirilumab

Cat. No.:	HY-P99208
CAS No.:	1000676-41-4
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research <sup>[1][2]</sup> .								
<b>In Vivo</b>	Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. <table><tr><td>Animal Model:</td><td>Rag1KO-Tg KIR mice injected with tumor cells<sup>[2]</sup></td></tr><tr><td>Dosage:</td><td>15 mg/kg</td></tr><tr><td>Administration:</td><td>intravenous injection; 15 mg/kg; once</td></tr><tr><td>Result:</td><td>Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.</td></tr></table>	Animal Model:	Rag1KO-Tg KIR mice injected with tumor cells <sup>[2]</sup>	Dosage:	15 mg/kg	Administration:	intravenous injection; 15 mg/kg; once	Result:	Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.
Animal Model:	Rag1KO-Tg KIR mice injected with tumor cells <sup>[2]</sup>								
Dosage:	15 mg/kg								
Administration:	intravenous injection; 15 mg/kg; once								
Result:	Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.								

### CUSTOMER VALIDATION

- Nat Commun. 2024 Jan 25;15(1):752.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

- [1]. Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478.
- [2]. Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA